Publication of the activity report and financial information for the first half-year (April – Sept. 2018)

December 3, 2018

Period highlights
In the United States, our partner Teva Pharmaceuticals initiated a Phase III clinical study for an investigational long-acting treatment for schizophrenia. This is the final stage of clinical development before applying for marketing approval. This product formulation (mdc-IRM) is based on our proprietary technology.

Other products in development
•Initiation of non-clinical development activities of a second product in the Central
Nervous System (CNS) in partnership with Teva
• Launch of the first clinical trial (Phase II) in the United States of a product that aims to treat orthopaedic postoperative pain, in partnership with AIC

Enhanced financial visibility
• Cash of €11.4 million in available funds and €4.6 million in non-risky financial assets
• EIB loan: €7.5 million received (a further €12.5 million still available)
• Initial Public Offering: €31.4 million (post-closing event)
• Increase in R&D spending: +23% (compared with the first half of 2017)

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.